TAAR1 and schizophrenia: At present, two independently developed TAAR1 agonists, Ulotaront (SEP-363856, SEP-856, Sunovion Pharmaceuticals Inc.)and Ralmitaront (RG-7906, RO-6889450, F. Hoffmann-La Roche AG), are being tested clinically for the treatment of schizophrenia [6] with the selective partial TAAR1 agonist Ralmitaront undergoing Phase 2 clinical trials and Ulotaront (full TAAR1 agonist with serotonin 5-HT1A agonist activity) being investigated at Phase 3 clinical studies [8,9].